For instance, nivolumab, an inhibitor of the programmed cell death 1 (PD-1)/ligand (PD-L1) pathway, increased the 2-year survival rate of patients with stage IIIB/IV cancer from 16% to ∼30% (4). This evidence concerns the gene PDCD1 and cancer.